Krystal Biotech (KRYS) Consolidated Net Income (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Consolidated Net Income of $54.8 million for Q2 2026, up 42.87% year-over-year from $38.3 million in Q2 2025, and down 2.08% on a QoQ basis from $55.9 million in Q1 2026.
Krystal Biotech (KRYS) Consolidated Net Income (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Consolidated Net Income for 11 years, with the latest figure at $54.8 million in Q2 2026.
- Consolidated Net Income for Q2 2026 came in at $54.8 million, up 42.87% year-over-year; the trailing twelve-month figure through Jun 2026 was $241.5 million (up 64.58% YoY), and the FY2025 annual result was $204.8 million, up 129.74% from the prior year.
- Consolidated Net Income fell to $54.8 million in Q2 2026, from $55.9 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at $80.7 million in Q3 2023 and troughed at -$114.3 million in Q1 2023.
- A 5-year average of $5.8 million and a median of $21.4 million in 2024 frame the typical range for Consolidated Net Income.
- The widest annual swing landed in 2022, when Consolidated Net Income tumbled 106.66%; it then soared 3730.15% in 2025.
- A 5-year view of Consolidated Net Income shows it stood at -$34.0 million in 2022, then soared by 125.55% to $8.7 million in 2023, then soared by 423.62% to $45.5 million in 2024, then rose by 12.91% to $51.4 million in 2025, then grew by 6.57% to $54.8 million in 2026.
- Per Business Quant data, the three most recent Consolidated Net Income figures were $54.8 million in Q2 2026, $55.9 million in Q1 2026, and $51.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 54.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.77 Mn |
| Mar 31, 2026 | 55.94 Mn |
| Dec 31, 2025 | 51.39 Mn |
| Sep 30, 2025 | 79.37 Mn |
| Jun 30, 2025 | 38.38 Mn |
| Mar 31, 2025 | 35.73 Mn |
| Dec 31, 2024 | 45.48 Mn |
| Sep 30, 2024 | 27.17 Mn |
| Jun 30, 2024 | 15.57 Mn |
| Mar 31, 2024 | 932,000.00 |
| Dec 31, 2023 | 8.69 Mn |
| Sep 30, 2023 | 80.75 Mn |
| Jun 30, 2023 | -33.21 Mn |
| Mar 31, 2023 | -114.32 Mn |
| Dec 31, 2022 | -34.02 Mn |
| Sep 30, 2022 | -68.59 Mn |
| Jun 30, 2022 | -57.44 Mn |
| Mar 31, 2022 | -81.62 Mn |
| Dec 31, 2021 | -22.03 Mn |
| Sep 30, 2021 | -25.10 Mn |